Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study

To investigate the efficacy and safety of vibegron add-on therapy in men with persistent storage symptoms receiving α-1 blockers or PDE5 inhibitor for benign prostatic hyperplasia and then determine the independent factors affecting the efficacy of vibegron. Vibegron 50 mg was administered for 12 we...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Urology (Ridgewood, N.J.) N.J.), 2021-07, Vol.153, p.256-263
Hauptverfasser:	Ishikawa, Keisuke, Tsujimura, Akira, Miyoshi, Miho, Miyoshi, Yuto, Ogasa, Taiki, Hiramatsu, Ippei, Uesaka, Yuka, Nozaki, Taiji, Shirai, Masato, Mitsuhashi, Isao, Sugimura, Sosuke, Mizuno, Taiki, Noto, Kensho, Shigeta, Yasuhiro, Honda, Shinichi, Iwata, Shinji, Horie, Shigeo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic alpha-Antagonists - therapeutic use Aged Drug Therapy, Combination Humans Male Phosphodiesterase 5 Inhibitors - therapeutic use Prospective Studies Prostatic Hyperplasia - complications Prostatic Hyperplasia - drug therapy Pyrimidinones - therapeutic use Pyrrolidines - therapeutic use Urinary Bladder, Overactive - drug therapy Urodynamics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!